Subscribe
montego-shutterstock-com
montego / Shutterstock.com
3 July 2015Americas

Biosimilars market value could triple by 2020, says report

The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
The plausibility battleground at the EPO
9 November 2020   Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.
Biotechnology
Association calls for more biosimilar cancer therapies in Europe
11 October 2018   Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.
Americas
US FDA approves first biosimilar, keeps quiet on naming standards
9 March 2015   The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Europe
The plausibility battleground at the EPO
9 November 2020   Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.
Biotechnology
Association calls for more biosimilar cancer therapies in Europe
11 October 2018   Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.
Americas
US FDA approves first biosimilar, keeps quiet on naming standards
9 March 2015   The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.

More on this story

Europe
The plausibility battleground at the EPO
9 November 2020   Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.
Biotechnology
Association calls for more biosimilar cancer therapies in Europe
11 October 2018   Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.
Americas
US FDA approves first biosimilar, keeps quiet on naming standards
9 March 2015   The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.

More features

GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia